Results
Febrile neutropenia, cardiac failure, neutropenia, acute kidney injury
CARDIAC FAILURE, DISEASE PROGRESSION, FEBRILE NEUTROPENIA, NEUTROPENIA, ADVERSE EVENT, TUMOR LYSIS SYNDROME
Fourteen patients were enrolled in this study. The median age was 77.5 years (range = 61–84), with 78.6% over 75 years old. The most common grade ≥ 3 treatment-emergent adverse event was neutropenia (57.1%). Febrile neutropenia was the most frequent serious adverse event (21.4%). One patient developed treatment-related acute kidney injury, leading to discontinuation of treatment. Two patients died because of cardiac failure and disease progression that were judged not related to study treatment. No patients developed tumor lysis syndrome.